Experience with 4'-demethylepipodo-phyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside); VM-26; NSC-122819 in the treatment of malignant lymphosis.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D001791:Blood Platelet Disorders / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D005260:Female; D005960:Glucosides / Q000627:therapeutic use*; D006027:Glycosides / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011034:Podophyllotoxin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012075:Remission, Spontaneous; D013876:Thiophenes / Q000627:therapeutic use
D000970:Antineoplastic Agents; D005960:Glucosides; D006027:Glycosides; D013876:Thiophenes; D011034:Podophyllotoxin